Bioteque (4107) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
18 Feb, 2026Executive summary
Consolidated financial statements reviewed for the six months ended June 30, 2025 and 2024, with no material misstatements identified by independent auditors.
The group operates in manufacturing, trading, and selling medical consumables, with subsidiaries in the Philippines.
Financial highlights
Operating revenue for H1 2025 was NT$1,049,020 thousand, up 3.4% year-over-year from NT$1,015,015 thousand.
Net income for H1 2025 was NT$247,001 thousand, slightly down from NT$250,208 thousand in H1 2024.
Gross margin for H1 2025 was 43%, consistent with H1 2024.
Basic EPS for H1 2025 was NT$3.56, compared to NT$3.61 in H1 2024.
Cash and cash equivalents as of June 30, 2025 were NT$1,244,353 thousand.
Outlook and guidance
Adoption of new IFRS standards is not expected to have a significant impact; management is evaluating future standards.
No significant changes in capital management or segment structure anticipated.
Latest events from Bioteque
- Revenue and net income rose year-over-year, with higher margins and stable operations.4107
Q2 2026 - Q1 2026 saw higher revenue, net income, and margins, with a NT$5.50 dividend approved.4107Q1 2026
- Revenue and profit rose slightly, with stable margins and higher dividends amid strong cash flow.4107Q4 2025
- Q2 2023 saw double-digit profit growth, margin expansion, and strong cash flow.4107Q2 2024
- Revenue and net income increased year-over-year, with strong margins and stable operations.4107Q3 2024
- Net income rose 17% on 7% revenue growth, with higher dividends and strong cash flow.4107Q4 2024
- Revenue and net income grew year-over-year, with higher margins and a NT$5.00 dividend approved.4107Q1 2025
- Stable revenue and margins, higher dividends, but net income and EPS slightly declined.4107Q3 2025